Aptose Biosciences (NASDAQ:APTO) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com began coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research report issued on Saturday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright reissued a “buy” rating and set a $2.00 price target on shares of Aptose Biosciences in a research note on Tuesday, December 3rd.

Aptose Biosciences Price Performance

Shares of NASDAQ:APTO opened at $0.19 on Friday. Aptose Biosciences has a one year low of $0.13 and a one year high of $2.91. The company has a market cap of $11.60 million, a price-to-earnings ratio of -0.07 and a beta of 1.06. The firm has a 50 day simple moving average of $0.33 and a 200 day simple moving average of $0.53.

Institutional Investors Weigh In On Aptose Biosciences

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp increased its position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 401,750 shares of the biotechnology company’s stock after purchasing an additional 167,282 shares during the period. Sigma Planning Corp owned approximately 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent quarter. Institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.